Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01ADL
|
|||
| Former ID |
DIB013019
|
|||
| Drug Name |
Roledumab
|
|||
| Synonyms |
DMATRIA; LFB-R593; R-297; R-593; Anti-D human monoclonal antibody, Laboratoire Francais du Fractionnement et des Biotechnologies; R297 antibody (hematological disease), LFB; R297 antibody (hematological disease), Laboratoire Francais du Fractionnement et des Biotechnologies; Anti-RhD antibody (hematological disease), LFB; Anti-rhesus D mAB (hematological disease), LFB
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-9: 280-285] | Phase 2/3 | [1] | |
| Company |
LFB Biotechnologies
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Blood group Rh(D) polypeptide (RHD) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02287896) Pharmacokinetics and Safety of Roledumab, in RhD-negative Pregnant Women Carrying an RhD-positive Foetus. U.S. National Institutes of Health. | |||
| REF 2 | Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCgammaRIII, in healthy volunteers. Vox Sang. 2012 Oct;103(3):213-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.